China and US agree to extend trade tariff truce, says Li
Investing.com - Myriad Genetics (NASDAQ: MYGN) reported third quarter EPS of $-0.03, $0.03 better than the analyst estimate of $-0.06. Revenue for the quarter came in at $195.9M versus the consensus estimate of $200.9M.
Guidance
Myriad Genetics sees FY 2025 EPS of $-0.02-$0.02 versus the analyst consensus of $0.08.
Myriad Genetics sees FY 2025 revenue of $807.00M-$823.00M versus the analyst consensus of $916.00M.
Myriad Genetics’s stock price closed at $7.27. It is down -41.42% in the last 3 months and down -69.65% in the last 12 months.
Myriad Genetics saw 0 positive EPS revisions and 10 negative EPS revisions in the last 90 days. See Myriad Genetics’s stock price’s past reactions to earnings here.
According to InvestingPro, Myriad Genetics’s Financial Health score is "good performance".
Check out Myriad Genetics’s recent earnings performance, and Myriad Genetics’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar